CNTX-6016 is a cannabinoid agonist that has been shown in preclinical studies to be more than 16,000-fold selective for CB2 over CB1, with potential indications including diabetic and autoimmune neuropathic pain and chemotherapy-induced neuropathy.
CNTX-6016 is a cannabinoid agonist that has been shown in preclinical studies to be more than 16,000-fold selective for CB2 over CB1, with potential indications including diabetic and autoimmune neuropathic pain and chemotherapy-induced neuropathy.